New lecanemab-data to be presented at the AD/PD™ 2023 conference
Stockholm, March 23, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and its partner Eisai announced today that the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti-amyloid beta (Aβ) protofibril[1] antibody for the treatment of Alzheimer’s disease (AD), will be presented at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™) from March 28-April 1 in Gothenburg, Sweden and virtually. AD/PD is a key scientific event with a focus on improving the treatment of Alzheimer’s, Parkinson’s, and other